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The percentage of urological cancers is consider-
able. Of all of the cancer deaths in our country, 10% 
are urological; in men alone, 18% are urological. It is 
immediately obvious that a very important aspect of 
this specialty is the treatment of cancer. 
Of the 18 % urological deaths among males, 
more than half are due to cancers of the prostate. 
When a patient is seen with evidence of a metastasiz-
ing cancer and a search is made for the primary 
site or source, there is always a hope that it will 
be cancer of the prostate, because we can do a 
great deal for this cancer that cannot be done in 
many other cancers. 
A comparison of the various urological cancer 
deaths will show that cancer of the prostate is the 
most frequent. Second is carcinoma of the bladder, 
followed by kidney tumors. In comparing cancer of 
the prostate with other cancers in older men (men 
over 75), prostatic carcinoma is the most common 
cause of cancer deaths. If figures for cancer of the 
colon, rectum and stomach are combined, the re-
sulting figure is slightly in excess of that for prostatic 
tumors. The impressive fact is that cancer of the 
prostate is the most significant cause, makes the 
most widows, of all the cancers among older males. 
With every passing decade, the number of cancers 
that one finds in any autopsy series of older people 
increases steadily. It does not increase among the 
people with cirrhosis, perhaps because of the in-
creased circulating estrogens in older people who 
have hepatic cirrhosis. If men were to live for an 
indefinite period of time, practically all of them would 
die of cancer of the prostate. The secret weapon is 
the rectal examination to detect the prostatic nodule 
before it has developed to a more advanced stage. 
* This is a transcription, edited by Dr. Warren W. 
Koontz, Jr., of a lecture presented by Dr. Lattimer at the 
26th Annual Stoneburner Lecture Series, February 22, 
1973, at the Medical College of Virginia, Richmond. 
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Dr. Charles Huggins' classic cross sections of the 
prostate ( 4) showed that the cancerous, dark area 
is almost always in the posterior lamella against the 
rectum where the rectal finger can easily palpate the 
nodule. It is universally recognized that rectal pal-
pation of the nodule will disclose cancer in only 50% 
of the cases. Nevertheless, in the 50% where cancer 
exists, the extent of the cancer is usually more than 
one would suspect from what one can feel. Recently, 
I have had it brought to my attention very forcefully 
that an asymmetry of the prostate without any par-
ticular increase in firmness may be worthy of great 
attention. I have had several patients who related that 
their internist had detected an asymmetry two or 
three years prior to biopsy and diagnosis. The in-
strument we use for biopsies is one developed by Dr. 
Ralph Veenema. 
This instrument can be used with local anes-
thesia, but it is much easier with pentothal anes-
thesia. We prefer the Veenema instrument, 
however, since it gives a substantial fragment of tis-
sue as compared to the Silverman or Vim-Silverman 
needle biopsies. Inadequate specimens may prevent 
the pathologist from rendering a diagnosis. We also 
want larger fragments because we grow the biopsies 
in tissue culture. This gives not only a dimension of 
additional size, but also gives an opportunity to 
experiment with that patient's cancer to see what 
medications act best against it and to see how it 
might differ from others. 
Of the prostate tumors biopsied, 11 % were 
confined to the prostate. Bone scans, bone surveys, 
and marrow acid phosphatases have shown that 
55% of the prostate cancers have extended locally. 
There is still another substantial group that has 
extended beyond the confines of the pelvis. The 
treatment varies in these different groups. It is the 
first group that is amenable to radical excision; 
the second group may be amenable to radiotherapy 
plus hormone therapy. For the third group, one must 
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depend upon hormone therapy and hopefully, in the 
next few years, immunotherapy. 
Only 13 % of patients with prostatic cancer 
were detected at an operable stage. The periodic rec-
tal examination is a campaign which we must all 
wage. It affords the greatest chance of success for 
making a contribution in preventive medicine. The 
executive physical examinations that many com-
panies sponsor is one of the best programs in the 
area of prevention. Occasionally, we find cancer in 
the chips from a transurethral prostatectomy which 
we did not suspect from rectal palpation. Then we 
have the dilemma of whether cancer has been left in 
the capsule, and we may resect a little more after 
a while to see whether we have chips. A few patients 
have undergone radical prostatectomy. Since radical 
prostatectomy is difficult technically following trans-
urethral prostatectomy, we resort to radiotherapy 
plus hormones or just hormones alone. Following 
radical prostatectomy, we administer antiandrogen 
treatment in the form of castration and estrogens 
for every patient who will take what we consider to 
be our best advice. We have a substantial number of 
cases treated in this way and are awaiting the 20-
year follow-up to compare with surgery alone. 
When suprapubic or retropubic enucleation re-
veals cancer, we are better able to determine whether 
all of the tumor has been removed. If so, there is no 
need to go back and do a radical procedure. Fre-
quently, when the patient has been through a big 
operation, he is not anxious to undergo further 
operative therapy. We are building some experience 
with radiotherapy after enucleation. One of our wor-
ries was that strictures might be more common and 
indeed be a bad feature of this type of therapy, but 
this has not turned out to be true. 
We prefer the radical retropubic prostatectomy. 
We do not perform radical perineal prostatectomies 
except for instructional purposes or for a particular 
case where it seems to be indicated. With the radical 
perineal prostatectomy, there is no opportunity to in-
vestigate for nodal metastasis . 
The first and classical study that Nesbit and 
his group ( 5) compiled indicated that stilbestrol in-
creased the five-year survival of patients with pros-
tatic cancer. Orchidectomy was a little better and 
the combination was better than either one alone. 
The Veterans Administration report (2) has in-
dicted stilbestrol therapy as a cause of coronary 
artery disease, phlebitus, and perhaps cerebral artery 
disease. In the wave of shock and enthusiasm on 
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their part they have gone overboard and have dis-
couraged a number of physicians from using stil-
bestrol. 
Castration, however, is a more certain way of 
obtaining an antiandrogenic effect and has none of 
the drawbacks that stilbestrol itself might have. We 
combine hormone therapy, or antiandrogens with 
castration. Castration is not of great importance to 
most of our patients. Their sex life has almost ended 
by the time we see them for their cancers, and they 
do not mind trading a better life expectancy for 
castration. Bony metastases of considerable extent 
will clear remarkably with antiandrogen treatment, 
and likewise, pulmonary metastases have cleared. 
Drawing on Dr. Huggins' experience (3), we 
have an interesting bit of information. A patient with 
metastases from a cancer of the prostate, proven by 
biopsy, was given stilbestrol by Dr. Huggins. He was 
left with just one or two metastases. Dr. Huggins 
then performed an orchidectomy and the nodules 
disappeared. Thi.Is we have two different modes of 
action with these two agents. A combination will be 
more effective than either one alone. It is not just 
an additive but it is a different action. 
A patient with cancer of the prostate which had 
obstructed the ureter was benefited by radiotherapy 
in shrinking the prostate. He was given 6,000 r of 
radiotherapy to the prostate area and the obstruc~ 
tion was relieved. The enthusiasts for this particular 
method of therapy, and particularly Dr. Malcolm 
Bagshaw ( 1), have put together a very large number 
of patients treated more or less with radiotherapy 
alone. Their success rate has been so good that 
they tell us that radiotherapy is curative. Raimey 
( 6), however, has produced at least a dozen cases 
where he has biopsied the prostate after radiotherapy 
and the cancer appeared exactly as before radio-
therapy. He argues that the cancer is not cured. 
Bagshaw replies that it looks like cancer but is not 
cancer and will not grow. Time will tell whether 
radiotherapy is really effective. Supervoltage therapy 
and perhaps larger doses and better targeting are 
improving results and the question is whether radio-
therapy is as good as radical prostatectomy. 
The Veterans Administration study suggests that 
conservative therapy is as good as radical surgery, 
but my view, after reviewing all of the studies, is 
that we do not yet know whether radiotherapy is in-
deed as good. 
The next question concerns combining radio-
therapy with antiandrogen therapy. Will that be as 
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good as a radical operation? At this moment, we do 
not know. We do know that if we remove the tumor, 
at least we are rid of the major part of the focus. 
The question remains, what about the cells that are 
spilled or that have migrated away? In reply to that 
question, one can demonstrate various experiments 
where a large mass of cancer treated by any modality 
has no great chance of shrinking. If the large 
tumor mass is removed and you leave behind only a 
few cells, then you may indeed kill those few cells 
by whatever supplementary means you use. We must 
look in the future to taking out the mass of cancer 
and then successfully treating what is left behind 
by immunological, hormonal means or by x-ray. We 
must think in terms of combination, and in my mind 
it is not entirely clear whether the radiation therapy 
plus hormone treatment is as good as surgery alone 
or surgery plus hormone treatment. 
Occasionally, there will be a massive cancer 
and the resectoscope will be necessary to tunnel an 
opening through it. This can be done and supple-
mented by other treatments. Another modality for 
this problem is freezing the prostate. We insert a 
cryoprobe much in the same location as the resec-
toscope sheath. The temperature is dropped to minus 
170° F and the mass of prostate freezes completely 
solid. It looks like a ball of ice, and literally, it is a 
ball of ice. Over the course of the next few weeks, 
the prostate will then slough. A catheter may have to 
remain in place for quite a long time while the gelati-
nous slough is removed. Later, there will be a very 
satisfactory tunnel through the middle of the pros-
tate, whether it is benign or malignant. 
There has been some suggestion that the very 
act of freezing will set up an immune reaction in 
the body wherein the body will attempt to reject, not 
only the frozen prostate, but also perhaps the metas-
tases. There is some encouraging evidence of this, 
and we have research going on presently in this field. 
We have been freezing the prostate three times, a 
so-called triple-freeze, and this is alleged to improve 
the immunological response and is a new dimension 
that is worth testing. It is not certain that it will be 
as good as we would like but, nevertheless, bone pain 
does diminish. 
If the prostate tumor appears to be resectable, 
we prefer to use the suprapubic approach. Our opera-
tion involves dividing the uretha just beyond the 
apex, dividing the vasa, dissecting the seminal vesi-
cles down to their tips and dividing the vessels. 
We take the fascia around the seminal vesicles pur-
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posely because we have found that this is the first 
route of extension of the disease outside of the 
prostate. We also remove a cuff of bladder. 
We take pieces of tissue from a benign area 
and pieces from the cancerous area and grow them 
in a medium that is laced with radioactive food in 
the form of thymidine and cytidine. We then make a 
radioautograph of this and determine the DNA and 
RNA synthesis rates in these various areas. We find 
a very clear picture of benign activity in the be-
nign areas and a very clear picture of greater ac-
tivity (five or six times as much mitosis) in the can-
cerous area. Dr. Myron Tannenbaum, one of our 
researchers, has found that the area surrounding the 
cancer was as active as the cancerous area. This sur-
prised him, and he then subjected the cells from this 
area to a higher magnification and discovered some 
very interesting material in what we refer to as the 
demilitarized zone, just outside the cancer. 
The cancers of the prostate are histologically 
so much like cancers of the breast that we run a 
lot of parallel work in the two fields. Dr. Tannen-
baum looked at cancers of the breast and found the 
same virus-like material in them. Turned on edge, 
the rods of the material look more target-like. Look-
ing at the cancers themselves in both the breast and 
in the prostate, he found the virus-like material in 
the lumen of the prostate and the breast. A different 
kind of virus-like particle, the so-called "C" particle 
has been found in the milk of a mouse with breast 
cancer as well as in the semen of her mate. A similar 
"C" particle has been found in the semen of one of 
our patients with cancer of the prostate. We are now 
heavily involved in antibody testing of all of our pa-
tients and their wives to see if there is any possible 
relationship between cancers of the prostate in men 
and cancer of the breast or genitalia in their wives. 
We studied 5,000 men and found 186 men with 
cancer of the prostate, where the wife had been living 
and having intercourse with him for at least two 
years before the diagnosis of cancer of the prostate 
was made. We found 8-9% of the wives of those pa-
tients had cancer of the breast. When one compares 
this with the expected incidence of such a group, it is 
500 times more. From this very carefully controlled 
group, it was found that the controls had an inci-
dence of less than 1 %-a finding of more than just 
passing interest. From this work we now advise that 
all of the wives of patients with cancer of the prostate 
have a very. careful breast examination, cervical Pap 
smear and ovarian examination at least every six 
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months. We have been cautious about stirring up a 
lot of anxiety where it might be unfounded, but 
knowing these facts and saying nothing would not be 
right either. We consider it advisable to be cautious 
in the campaign of encouraging the wives of men 
with cancer of the prostate to be examined more 
carefully and conscientiously than wives in the gen-
eral population. 
It is possible to take a time-lapse picture of a 
cancer cell and see what happens as it begins to 
divide. First, a refractive outer coat appears as the 
cell goes from the resting configuration to the stage 
where it is about to divide. The chromosomal ma-
terial begins to shape into a spindle and starts to di-
vide. Then the spindle forms very decidedly and 
some minutes later, there are two sets of chromo-
somes, divided and beginning to pull apart. They 
pull apart further, and two cells begin to form, now 
having a configuration more like the resting phase. 
If you know how many frames per second or per 
minute are involved in these changes, you can time 
the intervals between each of these phases. We 
usually take two-to-four frames per minute. The can-
cer cells take longer to divide than the normal cells, 
but the cancer cells go through this procedure much 
more often than the normal cells. An eye dropper 
can be used to add various anticancer medications 
to the culture to see how the course of events can be 
influenced. If the mitotic process stops, one can see 
in what phase it stops. The anticancer agents can 
be labeled and observed as they go into the cell. If 
the particles are fine enough and are hooked up to 
an immunological apparatus, it is possible to discover 
where they went in the cell. The technical aspects of 
this procedure pertain to the fact that some drugs 
go into the cell wall, some into the mitochondria, 
some into the nucleus, and other drugs act on the 
nucleolus. If one is using multiple drugs, it is helpful 
to have different modes of action. We have done this 
with the Wilms' tumor drugs and have sorted them to 
determine the actions of the different medications and 
have been able to obtain some information about the 
different modes of action and the most effective com-
binations. In spite of this technical apparatus, we 
still find the most important single case-finding fac-
tor influencing the successful treatment of this pros-
tate cancer to be the periodic rectal examination. 
Another aspect of scientific advancement is the 
fact that the cancers have caused the development 
of various immunological changes in the blood 
stream. Sometimes various antigens and antibodies 
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are present. There has been a rekindling of enthusi-
asm about this. Certain carcinomas of the bowel 
and certain embryological pieces of bowel give off 
antigens into the blood that can be measured quite 
easily. We have discovered that in various urological 
cancers this same antigen, called a cancer-associated 
antigen or a carcinoma embryonic antigen, is detecta-
ble. We have demonstrated that in various samples 
of prostate from various samples of the patient popu-
lation, we would find an increased and measurable 
amount of tumor-associated antigen that would not 
be of any value as a screening test because it was not 
always positive. Yet it did have value as a test of 
failure of treatment. If one surgically removed the 
prostate in a cancer patient and the test became 
negative, that was a good sign. If the test remained 
positive following surgery, one would know that all 
of the tumor had not been removed. Therefore, one 
might be more vigorous with the antiandrogenic or 
irradiation treatments. We have used it as an index 
of failure in radiotherapy cases where the first portal 
was mapped out and treatment included the prostate 
only. If the test remained positive, then we knew we 
had failed to kill all of the cancer arid we then 
irradiated to a larger field. Thus the test does have 
some usefulness even in its present crude form. The 
obvious implications are that we may be able to 
develop an antigenic test specifically for the prostate. 
This is what we are working on and I am sure others 
are investigating it also. This field is of considerable 
importance and interest. 
We have used the same tumor-associated anti-
gen, hooking it onto a bridging-type of enzyme sub-
stance, onto which can be hung a color, namely a 
reddish-brown color. If the tumor is positive with 
this antigen, we can treat the patient with this ma-
tedal and the cancerous areas will turn a very 
distinctive color. In a lymph node where the cancer 
is not obvious and where, by ordinary investigation, 
that is light microscopy, it may not be possible to tell 
that these areas are cancerous, this test will show 
that the node is very specifically cancerous. 
The same technique might be applied to the 
Pap smear to ascertain whether there are cancerous 
cells in tissues. With the electron microscope, one can 
tell for sure, but you cannot scan wall-to-wall with 
the electron microscope. With the antigen, it would 
be possible to pinpoint the areas that turned red and 
go directly to them with the electron microscope. 
We may be able to apply our greater scientific capa-
bility to the clinical staging of the cancer and thus 
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bring about a more specific and accurate staging 
and treatment. The implications of this are con-
siderable. 
Our only protection against cancer of the pros-
tate and its rapid growth is the annual physical 
examination. We know that various cancers divide 
at different rates. We do not know the reasons for 
all of the differences. We do not even know why one 
person develops a prostatic cancer and the next does 
not. The fact that it is endocrinologically dependent, 
the fact that it is possible to survey what goes on in 
great detail through the capabilities that we have 
makes the urological specialty very valuable in the 
cancer area. 
We are able to study the rate of growth, re-
gression or improvement of solid tumors of the kid-
ney through pyelography, aortography and angio-
graphy better than other fields. Epithelial tumors of 
the bladder can be observed with the cytoscope and 
biopsied periodically to follow the efficacy of treat-
ment or to get specimens for study. Hormone-depend-
ent therapy in cancer of the prostate gives us more 
leverage and opportunity to study the activity of 
cancer. The advances that have been accomplished, 
in fact some of the great success stories of cancer, 
have been urological. I think the prostate was cer-
tainly the bellwether of all the demonstrations that 
a hormone-dependent cancer could be influenced. I 
think it is part of our responsibility as urologists to 
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realize that we have this opportunity. I know that all 
of you share with me this enthusiasm to do every-
thing we can and to be in a position for contributing 
more than any other specialty to the study of cancer. 
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